Damora Therapeutics (DMRA) Receivables Refunds (2019 - 2026)
Damora Therapeutics posted quarterly Receivables Refunds of $854000.0 for Q1 2026, down 1.73% year-on-year from $869000.0 in Q1 2025, and down 2.4% on a QoQ basis from $875000.0 in Q4 2025.
Damora Therapeutics (DMRA) has 8 years of Receivables Refunds data on file, last reported at $854000.0 in Q1 2026.
- For the quarter ending Q1 2026, Receivables Refunds fell 1.73% year-over-year to $854000.0; the trailing twelve-month figure through Mar 2026 stood at $854000.0 (down 1.73% YoY), and the FY2025 full-year result was $875000.0, up 4.67% from the prior year.
- Receivables Refunds for Q1 2026 stood at $854000.0, down from $875000.0 in the prior quarter.
- Across five years, Receivables Refunds topped out at $1.4 million in Q2 2024 and bottomed at $26000.0 in Q2 2025.
- The 5-year median for Receivables Refunds is $774000.0 (2022), against an average of $644705.9.
- The widest annual swing landed in 2024, when Receivables Refunds surged 269.74%; it then tumbled 98.2% in 2025.
- A 5-year view of Receivables Refunds shows it stood at $587000.0 in 2022, then slumped by 52.3% to $280000.0 in 2023, then soared by 198.57% to $836000.0 in 2024, then rose by 4.67% to $875000.0 in 2025, then dropped by 2.4% to $854000.0 in 2026.
- The last three Receivables Refunds figures came in at $854000.0 (Q1 2026), $875000.0 (Q4 2025), and $28000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Refund Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Damora Therapeutics | 853.36 Mn | 650.97 Mn | - | 854,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 854,000.00 |
| Dec 31, 2025 | 875,000.00 |
| Sep 30, 2025 | 28,000.00 |
| Jun 30, 2025 | 26,000.00 |
| Mar 31, 2025 | 869,000.00 |
| Dec 31, 2024 | 836,000.00 |
| Sep 30, 2024 | 949,000.00 |
| Jun 30, 2024 | 1.44 Mn |
| Mar 31, 2024 | 283,000.00 |
| Dec 31, 2023 | 280,000.00 |
| Sep 30, 2023 | 419,000.00 |
| Jun 30, 2023 | 390,000.00 |
| Mar 31, 2023 | 804,000.00 |
| Dec 31, 2022 | 587,000.00 |
| Sep 30, 2022 | 724,000.00 |
| Jun 30, 2022 | 774,000.00 |
| Mar 31, 2022 | 820,000.00 |
| Dec 31, 2021 | 1.68 Mn |
| Sep 30, 2021 | 856,000.00 |
| Jun 30, 2021 | 876,000.00 |
| Mar 31, 2021 | 868,000.00 |
| Dec 31, 2020 | 1.81 Mn |
| Sep 30, 2020 | 863,000.00 |
| Dec 31, 2019 | 827,000.00 |